Sara Motka: We Create Greater Synergies Between Haemophilia and Haemoglobinopathies
Sara Motka, Head of Programmes at the Novo Nordisk Haemophilia and Haemoglobinopathies Foundation, reposted from Novo Nordisk Haemophilia and Haemoglobinopathies Foundation on LinkedIn:
”Thrilled to announce the expansion of NNHF! We will amplify our efforts in data-driven advocacy, forge stronger partnerships, and create greater synergies between haemophilia and haemoglobinopathies. Our mission goes beyond connecting and building opportunities for the global bleeding disorders community; we will aim to make a meaningful contribution to sickle cell disease and thalassaemia too. We will continue to connect, enable, and accelerate. Impacting care – Together!”
Qutoing Novo Nordisk Haemophilia and Haemoglobinopathies Foundation‘s post:
”We are now the Novo Nordisk Haemophilia and Haemoglobinopathies Foundation!
Proudly, we are unveiling our Foundation’s new chapter:
We are expanding our support beyond people with haemophilia to people with sickle cell disease and thalassaemia as well.
Building on two decades of work in haemophilia, and enabled by a renewed partnership with the Novo Nordisk Foundation and the continued funding from our founder Novo Nordisk, we are expanding our scope to include haemoglobinopathies. We will apply our proven, partnership-led model to develop tailored programmes that benefit people with haemophilia and haemoglobinopathies, their healthcare professionals, and families – always adapted to local needs.
Let us tell you more here.
Ludovic Helfgott, Mads Krogsgaard Thomsen, Maziar Mike Doustdar, Amy Shapiro, Stephanie Seremetis, Johnny Mahlangu, Ognenka Kozar, Denise B., Amos Gitonga M, Llyord Mwaniki, Célia Rohrer, Gatoto Carole, Sara Motka, Xio Fong Vilaysane, Elisa Eleftheriou, Natasha Honan.”
Stay updated with Hemostasis Today.
-
Jan 22, 2026, 15:36We Must Roll Up Our Sleeves And Help: José Antonio García Erce on Plasma Donation
-
Jan 22, 2026, 15:25Nita Radhakrishnan on Challenges In Congenital Afibrinogenemia
-
Jan 22, 2026, 15:10Jin Q Gives a Summary of 2025’s Most Impactful Cell and Gene Therapy Milestones
-
Jan 22, 2026, 14:57Nirav Dhanesha on CD14 Acting As A Functional Driver of DVT
-
Jan 22, 2026, 11:41Jamilla Goedegebuur and Colleagues on VTE Management in Case of PAD
-
Jan 22, 2026, 11:28Abdulrahman Katib on API-CAT Trial’s Evaluation of Apixaban Dosing
-
Jan 22, 2026, 11:19Bruno Odisio: Ablation Margins Are Software-Dependent
-
Jan 22, 2026, 10:38Pedro Perez: The VTE Market Is Clearly Entering Its Next Phase
-
Jan 22, 2026, 10:29Marvin Garcia Reyes Presents a Case of Aorto-Visceral and Aorto-Iliac Thrombosis